APA (7th ed.) Citation

I, Z., M, T., A, O., JC, S., V, G., DF, M., . . . C, F. d. L. (2025). Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. Blood advances, 9(3), 571. https://doi.org/10.1182/bloodadvances.2024014360

Chicago Style (17th ed.) Citation

I, Zugasti, et al. "Clinical Impact of [18F]FDG-PET/CT in ARI0002h Treatment, a CAR-T Against BCMA for Relapsed/refractory Multiple Myeloma." Blood Advances 9, no. 3 (2025): 571. https://doi.org/10.1182/bloodadvances.2024014360.

MLA (9th ed.) Citation

I, Zugasti, et al. "Clinical Impact of [18F]FDG-PET/CT in ARI0002h Treatment, a CAR-T Against BCMA for Relapsed/refractory Multiple Myeloma." Blood Advances, vol. 9, no. 3, 2025, p. 571, https://doi.org/10.1182/bloodadvances.2024014360.